Mifepristone

Corcept's CATALYST trial showed Korlym significantly reduced hemoglobin A1c by 1.47% vs 0.15% in placebo group (p<0.0001). 23.8% of 1,057 screened diabetes patients had hypercortisolism; 136 were treated. Safety profile consistent with Korlym's label.

Corcept Therapeutics announced results from the DAZALS study, a Phase 2 trial evaluating dazucorilant in ALS patients. The study did not meet its primary endpoint, but showed fewer deaths in the 300 mg arm compared to placebo. An open-label extension study will continue, with overall survival assessed in 2025. Dazucorilant has Fast Track Designation from the FDA.

Trump's reelection may boost biotech innovation and M&A activity, potentially repealing the Inflation Reduction Act. Key roles in federal health agencies will influence drug pricing reforms. The Zacks Medical-Drugs industry, despite headwinds, shows promising trends with innovation in diabetes/obesity, inflammation, and neuroscience. Small drugmakers rely on collaboration partners and R&D funding, with notable stocks including Corcept Therapeutics, Madrigal Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, and Larimar Therapeutics.

Corcept Therapeutics reports Q3 2024 revenue of $182.5M, up 48% YoY, and increases 2024 revenue guidance to $675-$700M. Net income per share is $0.41 (diluted), with cash and investments at $547.6M. The company plans to submit an NDA for relacorilant this quarter, supported by Phase 3 GRADIENT trial results.